Search research articles
Contact Us
Filters
Showing results (151-160 of 168) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Neelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
Beverly Moy, R Bryan Rumble, Steven E Come, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
JAMA Internal Medicine
|
April 27, 2026
Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial
Folasade P May, Suzanne Brodney, Jessica J Tuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M Tolaney, Hao Guo, Sonia Pernas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
Seth A Wander, Hyo S Han, Mark L Zangardi, et al.
Clinical Breast Cancer
|
November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan, Beverly Moy, Janine Mansi, et al.
The Lancet. Oncology
|
April 30, 2026
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial
Seth A Wander, Maxwell R Lloyd, Jennifer C Keenan, et al.
The Lancet. Oncology
|
March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M Tolaney, Paolo Tarantino, Noah Graham, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 168) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2020
Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Neelima Vidula, Taronish Dubash, Michael S Lawrence, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
Beverly Moy, R Bryan Rumble, Steven E Come, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
The Lancet. Oncology
|
February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan, Suzette Delaloge, Frankie A Holmes, et al.
JAMA Internal Medicine
|
April 27, 2026
Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial
Folasade P May, Suzanne Brodney, Jessica J Tuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M Tolaney, Hao Guo, Sonia Pernas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
Seth A Wander, Hyo S Han, Mark L Zangardi, et al.
Clinical Breast Cancer
|
November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan, Beverly Moy, Janine Mansi, et al.
The Lancet. Oncology
|
April 30, 2026
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial
Seth A Wander, Maxwell R Lloyd, Jennifer C Keenan, et al.
The Lancet. Oncology
|
March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M Tolaney, Paolo Tarantino, Noah Graham, et al.
Page
of 17